Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imaging-therapy computed tomography with quasi-monochromatic X-rays.
Jost G, Golfier S, Lawaczeck R, Weinmann HJ, Gerlach M, Cibik L, Krumrey M, Fratzscher D, Rabe J, Arkadiev V, Haschke M, Langhoff N, Wedell R, Luedemann L, Wust P, Pietsch H. Jost G, et al. Among authors: golfier s. Eur J Radiol. 2008 Dec;68(3 Suppl):S63-8. doi: 10.1016/j.ejrad.2008.04.040. Epub 2008 Jun 30. Eur J Radiol. 2008. PMID: 18586430
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Sieber MA, et al. Among authors: golfier s. Eur Radiol. 2008 Oct;18(10):2164-73. doi: 10.1007/s00330-008-0977-y. Epub 2008 Jun 11. Eur Radiol. 2008. PMID: 18545998
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS. Hagemann UB, et al. Among authors: golfier s. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7. Clin Cancer Res. 2019. PMID: 31064781
3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions.
Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, Osterland M, Golfier S, Räse S, Ansari N, Esner M, Bickle M, Pampaloni F, Mattheyer C, Stelzer EH, Parczyk K, Prechtl S, Steigemann P. Wenzel C, et al. Among authors: golfier s. Exp Cell Res. 2014 Apr 15;323(1):131-143. doi: 10.1016/j.yexcr.2014.01.017. Epub 2014 Jan 27. Exp Cell Res. 2014. PMID: 24480576 Free article.
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Willuda J, Linden L, Lerchen HG, Kopitz C, Stelte-Ludwig B, Pena C, Lange C, Golfier S, Kneip C, Carrigan PE, Mclean K, Schuhmacher J, von Ahsen O, Müller J, Dittmer F, Beier R, El Sheikh S, Tebbe J, Leder G, Apeler H, Jautelat R, Ziegelbauer K, Kreft B. Willuda J, et al. Among authors: golfier s. Mol Cancer Ther. 2017 May;16(5):893-904. doi: 10.1158/1535-7163.MCT-16-0474. Epub 2017 Mar 14. Mol Cancer Ther. 2017. PMID: 28292941
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Müller-Tiemann B, Kreft B, Ziegelbauer K. Golfier S, et al. Mol Cancer Ther. 2014 Jun;13(6):1537-48. doi: 10.1158/1535-7163.MCT-13-0926. Epub 2014 Apr 8. Mol Cancer Ther. 2014. PMID: 24714131
31 results